3 results
Sodium-glucose cotransporter 2 (SGLT2) inhibitors lead to a lowering of blood pressure and confer cardiovascular and renal protection in many, but not all people with type 2 diabetes (T2D), possibly due to a difference in sodium intake. with this…
Despite multifactorial treatment approaches residual risk for the development and progression of DKD remains high and novel therapies to halt renal burden in T2DM are urgently needed. SGLT-2 inhibitors are a relatively recent additions to the…
The objective of this study is to investigate the safety and effectiveness of different combinations of cancer immunotherapies compared to either Nivolumab or Ipilimumab, as determined by comparing the Overall Response Rate, at 24 weeks in patients…